Payer Predictions: Evolution of the U.S. Digital Therapeutics Reimbursement Landscape
Available On Demand
The digital therapeutics (DTx) market is growing rapidly, but a lack of clarity around their reimbursement framework in the U.S. means that there is limited coverage. DTx developers— and pharmaceutical organizations seeking an integrated digital offering— are left to wonder how the payer landscape will evolve as they strategize for the future.
Join Trinity Life Sciences’ MedTech and Evidence, Value, Access and Pricing experts as they explore what the future DTx reimbursement landscape might look like, drawing upon detailed first-hand insights from medical and pharmacy directors at large U.S. payer organizations.
Key Webinar Topics:
- Overview of DTx and the current reimbursement landscape in the U.S.
- Case Study: How a DTx developer is navigating the challenges of commercializing prescription DTx – what level of evidence is good enough?
- Payer predictions about the evolution of DTx coverage
- Implications for DTx developers, pharmaceutical manufacturers, providers and patients